article thumbnail

A human interactome to prioritize drug discovery

Medical Xpress

Scientists at Open Targets, EMBL's European Bioinformatics Institute (EMBL-EBI), and GSK are revealing the shared basis of diseases using a map of interacting human proteins.

article thumbnail

PanOmics: Advancing drug discovery

Drug Discovery World

The technologies cover the whole range of biomolecules from genes to protein to metabolites. With the ability to analyse thousands of proteins simultaneously, proteomics empowers scientists to reveal previously unknown protein interactions, pathways, and drug targets. phosphorylations or ubiquitinations).

Drugs 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Computer vision helps find binding sites in drug targets

Scienmag

Scientists from the iMolecule group at Skoltech Center for Computational and Data-Intensive Science and Engineering (CDISE) developed BiteNet, a machine learning (ML) algorithm that helps find drug binding sites, i.e. potential drug targets, in proteins. BiteNet can analyze 1,000 protein structures in 1.5

Drugs 59
article thumbnail

Looking ahead to AACR  

Drug Discovery World

The workshop will be led by hfp consulting, a firm which specialises in career development and leadership training for scientists. These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

Protein 52
article thumbnail

Drug discovery deals highlight key growth areas

Drug Discovery World

Its proprietary technology, Proximity Extension Assay (PEA), provides high throughput protein analysis. Through the purchase, Thermo Fisher will also gain a library of more than 5,300 validated protein biomarker targets. Olink specialises in solutions for proteomics discovery and development.

Drugs 52
article thumbnail

Country focus: Hungary carves out a niche in digital pharma

pharmaphorum

“For example, you can simulate what would happen if you inhibited thousands of different proteins in thousands of different cell models.”. There are a lot of scientists who want to better understand biology but don’t have the money to do it in wet settings. They go into bioinformatics”. They go into bioinformatics.”.

article thumbnail

Researchers identify immune targets for chemotherapy-resistant breast cancers

Drug Discovery World

To investigate the immune environment that surrounds these chemotherapy-resistant tumours, the researchers employed multiple and novel complementary technologies looking at proteins and genes on both pre-treatment and post-treatment breast cancer tissue.